Janssen Biotech Inc.

09/14/2024 | Press release | Distributed by Public on 09/14/2024 11:01

RYBREVANT® (amivantamab vmjw) plus chemotherapy shows positive overall survival trend versus chemotherapy in patients with previously treated EGFR mutated lung cancer